Literature DB >> 24900387

Discovery of a novel chemotype of tyrosine kinase inhibitors by fragment-based docking and molecular dynamics.

Hongtao Zhao1, Jing Dong1, Karine Lafleur1, Cristina Nevado1, Amedeo Caflisch1.   

Abstract

We have discovered a novel chemical class of inhibitors of the EphB4 tyrosine kinase by fragment-based high-throughput docking followed by explicit solvent molecular dynamics simulations for assessment of the binding mode. The synthesis of a single derivative (compound 7) of the hit identified in silico has resulted in an improvement of the inhibitory potency in an enzymatic assay from 8.4 μM to 160 nM and a ligand efficiency of 0.39 kcal/mol per non-hydrogen atom. Such remarkable improvement in affinity is due to an additional hydroxyl group involved in two favorable (buried) hydrogen bonds as predicted by molecular dynamics and validated by the crystal structure of the complex with EphA3 solved at 1.7 Å resolution.

Entities:  

Keywords:  EphB4 kinase; In silico screening; angiogenesis; cancer; explicit solvent MD

Year:  2012        PMID: 24900387      PMCID: PMC4025670          DOI: 10.1021/ml3001984

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  22 in total

1.  Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.

Authors:  Li Sun; Chris Liang; Sheri Shirazian; Yong Zhou; Todd Miller; Jean Cui; Juri Y Fukuda; Ji-Yu Chu; Asaad Nematalla; Xueyan Wang; Hui Chen; Anand Sistla; Tony C Luu; Flora Tang; James Wei; Cho Tang
Journal:  J Med Chem       Date:  2003-03-27       Impact factor: 7.446

Review 2.  Targeting Eph receptors with peptides and small molecules: progress and challenges.

Authors:  Roberta Noberini; Ilaria Lamberto; Elena B Pasquale
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

3.  ZINC--a free database of commercially available compounds for virtual screening.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

Review 4.  CHARMM: the biomolecular simulation program.

Authors:  B R Brooks; C L Brooks; A D Mackerell; L Nilsson; R J Petrella; B Roux; Y Won; G Archontis; C Bartels; S Boresch; A Caflisch; L Caves; Q Cui; A R Dinner; M Feig; S Fischer; J Gao; M Hodoscek; W Im; K Kuczera; T Lazaridis; J Ma; V Ovchinnikov; E Paci; R W Pastor; C B Post; J Z Pu; M Schaefer; B Tidor; R M Venable; H L Woodcock; X Wu; W Yang; D M York; M Karplus
Journal:  J Comput Chem       Date:  2009-07-30       Impact factor: 3.376

5.  Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.

Authors:  Hongtao Zhao; Danzhi Huang; Amedeo Caflisch
Journal:  ChemMedChem       Date:  2012-09-13       Impact factor: 3.466

6.  Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.

Authors:  Massimiliano Tognolini; Matteo Incerti; Iftiin Hassan-Mohamed; Carmine Giorgio; Simonetta Russo; Renato Bruni; Barbara Lelli; Luisa Bracci; Roberta Noberini; Elena B Pasquale; Elisabetta Barocelli; Paola Vicini; Marco Mor; Alessio Lodola
Journal:  ChemMedChem       Date:  2012-04-23       Impact factor: 3.466

7.  The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis.

Authors:  Georg Martiny-Baron; Philipp Holzer; Eric Billy; Christian Schnell; Joseph Brueggen; Mireille Ferretti; Niko Schmiedeberg; Jeanette M Wood; Pascal Furet; Patricia Imbach
Journal:  Angiogenesis       Date:  2010-08-29       Impact factor: 9.596

8.  Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis.

Authors:  Danzhi Huang; Ting Zhou; Karine Lafleur; Cristina Nevado; Amedeo Caflisch
Journal:  Bioinformatics       Date:  2009-11-26       Impact factor: 6.937

9.  Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines.

Authors:  Catherine Bardelle; Darren Cross; Sara Davenport; Jason G Kettle; Eun Jung Ko; Andrew G Leach; Andrew Mortlock; Jon Read; Nicola J Roberts; Peter Robins; Emma J Williams
Journal:  Bioorg Med Chem Lett       Date:  2008-04-10       Impact factor: 2.823

10.  Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.

Authors:  Yongmun Choi; Farisa Syeda; John R Walker; Patrick J Finerty; Dominic Cuerrier; Amy Wojciechowski; Qingsong Liu; Sirano Dhe-Paganon; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2009-05-13       Impact factor: 2.823

View more
  6 in total

1.  Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases.

Authors:  Jing Dong; Hongtao Zhao; Ting Zhou; Dimitrios Spiliotopoulos; Chitra Rajendran; Xiao-Dan Li; Danzhi Huang; Amedeo Caflisch
Journal:  ACS Med Chem Lett       Date:  2014-09-29       Impact factor: 4.345

2.  In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4.

Authors:  Yoel Rodríguez; Guillermo Gerona-Navarro; Roman Osman; Ming-Ming Zhou
Journal:  Proteins       Date:  2019-10-21

3.  Fragment-based docking: development of the CHARMMing Web user interface as a platform for computer-aided drug design.

Authors:  Yuri Pevzner; Emilie Frugier; Vinushka Schalk; Amedeo Caflisch; H Lee Woodcock
Journal:  J Chem Inf Model       Date:  2014-09-10       Impact factor: 4.956

4.  Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors.

Authors:  Andrea Unzue; Claudia Jessen-Trefzer; Dimitrios Spiliotopoulos; Eugenio Gaudio; Chiara Tarantelli; Jing Dong; Hongtao Zhao; Johanna Pachmayr; Stefan Zahler; Elena Bernasconi; Giulio Sartori; Luciano Cascione; Francesco Bertoni; Paweł Śledź; Amedeo Caflisch; Cristina Nevado
Journal:  RSC Med Chem       Date:  2020-05-19

Review 5.  Current Strategies and Applications for Precision Drug Design.

Authors:  Chen Wang; Pan Xu; Luyu Zhang; Jing Huang; Kongkai Zhu; Cheng Luo
Journal:  Front Pharmacol       Date:  2018-07-18       Impact factor: 5.810

Review 6.  In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs.

Authors:  Zarko Gagic; Dusan Ruzic; Nemanja Djokovic; Teodora Djikic; Katarina Nikolic
Journal:  Front Chem       Date:  2020-01-08       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.